T. Rowe Price Investment Management

Activity in this selectionOct 4, 2026 · Biotech · Jan 1, 2026

By stage

Series B2

Series C+1

Biotech3

United States3

3 in this selection

Jun 24

Develops bispecific antibody therapies for retinal vascular diseases including diabetic macular edema and wet AMD

$330MSeries B

Role not disclosed

Jan 28

Develops automated cell therapy manufacturing platforms

$257MSeries D

Role not disclosed

Jan 12

Develops next-generation therapies for immune-mediated inflammatory and fibrotic diseases

$250MSeries B

Role not disclosed